kaiser permanente glp-1 coverage news GLP-1s are powerful weight loss tools, but they're only part of the plan Kaiser is making it even

Kaplan LM, Golden A, Jinnett K, et al

Covering GLP-1s without structure is like paying for gym memberships no one uses

This suggests a potentially better lean mass to fat mass loss ratio with tirzepatide but the trials used different populations and protocols so direct comparison requires caution

Evidence for a class effect Several pieces of evidence suggest allodynia may be a GLP-1 receptor agonist class effect rather than specific to semaglutide

Improved kidney function: Recent developments in the management of T2D have identified the use of GLP-1s to reduce the progression of kidney disease in individuals with diabetes

By analyzing serum neuron-derived EVs, the study further explored how exenatide may modify brain insulin signaling pathways